 |
|
|
|
|
Table of Contents
- CHAPTER 1 EXECUTIVE SUMMARY
- Key findings
- Historical and forecast ethical sales performance
- Therapeutic strategy
- Launch and expiry outlook
- Externalization, geographic and molecule type strategies
- Externalization strategy
- Geographic strategy
- Molecule type strategy
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- CHAPTER 2 CORPORATE HISTORY
- Key findings
- Background
- Key corporate developments
- M&A history
- Current corporate structure
- Current management team
- CHAPTER 3 HISTORICAL PERFORMANCE
- Key findings
- Introduction
- Revenue and growth rate analysis, 2001-06
- Revenue and growth rate vs. peer set
- Product analysis, 2001-06
- Growth drivers
- Cipralex
- Lexapro royalties
- Ebixa
- Growth resistors
- Operating revenue and cost analysis, 2001-06
- Operating revenue/cost analysis
- CHAPTER 4 FORECAST PERFORMANCE
- Key findings
- Introduction
- Revenue and growth rate, 2006-12
- Product analysis, 2006-12
- Growth drivers
- Cipralex
- Ebixa
- Lexapro royalties
- Azilect
- sertindole
- Growth resistors
- Therapy area analysis, 2006-12
- Launches and expiries analysis, 2006-12
- Launch portfolio
- Core portfolio
- Expiry portfolio
- Launch/core/expiry configuration
- Externalization analysis, 2006-12
- Geographic analysis, 2006-12
- Molecule type analysis, 2006-12
- CHAPTER 5 KEY PRODUCTS AND COMPETITORS
- Key findings
- Overview
- CNS
- Cipralex (and Lexapro royalties)
- Overview
- Sales forecast
- Newsflow
- Competitive landscape
- Ebixa
- Overview
- Sales forecast
- Newsflow
- Competitive landscape
- R&D pipeline
- CHAPTER 6 APPENDIX
- IMS vs. company-reported data reconciliation
- Abbreviations
- Exchange rates
- List of Tables
- Table 1: Lundbeck Corporate Executive Committee
- Table 2: Peer set overview
- Table 3: Operating revenue/cost analysis ($m), 2001-06
- Table 4: Operating cost ratio analysis (% of total revenues), 2001-06
- Table 5: Product portfolio overview, sales ($m), 2006-12
- Table 6: Therapy area overview, sales ($m), 2006-12
- Table 7: Launch portfolio overview, sales ($m), 2006-12
- Table 8: Core portfolio overview, sales ($m), 2006-12
- Table 9: Expiry portfolio overview, sales ($m), 2006-12
- Table 10: Externally developed portfolio ($m), 2006-12
- Table 11: Molecule type overview, sales ($m), 2006-12
- Table 12: Key products overview
- Table 13: Cipralex: overview
- Table 14: Cipralex: sales forecast ($m), 2006-12
- Table 15: Cipralex: newsflow
- Table 16: Ebixa: overview
- Table 17: Ebixa: sales forecast ($m), 2006-12
- Table 18: Ebixa: newsflow
- Table 19: Lundbeck' s R&D pipeline (Phase I-registration)
- Table 20: Exchange rates, 2006
- List of Figures
- Figure 1: Historical and forecast ethical sales performance (% CAGR),
Lundbeck and Mid Pharma peer set
- Figure 2: Therapeutic focus vs. Mid Pharma peer set (%), 2006
- Figure 3: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), Lundbeck
- Figure 4: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), peer set
- Figure 5: Molecule type, externalization and geographic market
dependency (%) vs. peer set, 2006
- Figure 6: Molecule type, externalization and geographic market
dependency (%) vs. peer set, 2012
- Figure 7: SWOT analysis of Lundbeck
- Figure 8: Revenue & growth rate (ethical sales) ($m), 2001-06
- Figure 9: Ethical revenue ($m) and growth rate (%) vs. peer set,
2001-06
- Figure 10: Growth drivers/resistor products of historical revenue
performance ($m), 2001-06
- Figure 11: Operating revenue/cost analysis ($m), 2001-06
- Figure 12: Operating cost ratio analysis (% of total revenues), 2001-06
- Figure 13: Ethical revenue ($m) and growth rate (%), 2006-12
- Figure 14: Top five products by sales ($m), 2006
- Figure 15: Top five products by sales ($m), 2012
- Figure 16: Growth drivers and resistors by product, 2006-12
- Figure 17: Key strategic products, sales ($m), 2006-12
- Figure 18: Ethical sales by therapy area ($m), 2006-12
- Figure 19: Growth drivers and resistors by therapy area ($m), 2006-12
- Figure 20: Ethical sales by therapy area (%), 2006-12
- Figure 21: Therapy area focus compared with peer set (% total ethical
sales), 2006
- Figure 22: Therapy area focus compared with peer set (% total ethical
sales), 2012
- Figure 23: Launch schedule, sales ($m), 2006-12
- Figure 24: Core products sales growth ($m), 2006-12
- Figure 25: Expiry schedule, sales ($m), 2006-12
- Figure 26: Launch, core and expiry, sales ($m), 2006-12
- Figure 27: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), Lundbeck
- Figure 28: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), peer set
- Figure 29: Externalization dependency, sales ($m), 2006-12
- Figure 30: Growth drivers and resistors, externally vs. internally
discovered products, sales ($m), 2006-12
- Figure 31: Externalization dependency vs. peer set, % total sales, 2006
- Figure 32: Externalization dependency vs. peer set, % total sales, 2012
- Figure 33: Geographical sales breakdown ($m), 2006-12
- Figure 34: Growth drivers and resistors by geography, sales ($m),
2006-12
- Figure 35: US dependency vs. peer set, % total sales, 2006
- Figure 36: US dependency vs. peer set, % total sales, 2012
- Figure 37: Growth drivers and resistors by molecule type, sales ($m),
2006-12
- Figure 38: Molecule type sales breakdown ($m), 2006-12
- Figure 39: Biologics dependency vs. peer set, % total sales, 2006
- Figure 40: Biologics dependency vs. peer set, % total sales, 2012
- Figure 41: Lundbeck' s Cipramil/Cipralex switch (% total), 2002-05
- Figure 42: Forest' s Celexa/Lexapro switch (% total), 2002-05
- Figure 43: IMS vs. company-reported ethical sales discrepancy ($m),
2006
- Figure 44: IMS vs. company-reported ethical sales forecast growth
rates (%), 2006-12
|
|
|
|
|
|
View Cart
